RADL3

Strategic Conclusion

• Recommendation: Hold
• Why? The stock is trading above its 50-day moving average but still below the 200-day, reflecting a short-term recovery inside a medium-term downtrend. Valuation at 25.2x earnings is not cheap for a Brazilian retail/pharmacy name, while the RSI near 42.5 and the MACD turning positive suggest a neutral-to-cautiously-bullish technical setup. Without analyst support and with the price still far from the 52-week high, the risk/reward favors patience over aggressive buying.
• Ideal profile: Long-term investor with a 2+ year horizon, or a swing trader waiting for a clearer trend confirmation. Not ideal for short-term aggressive traders.
• Price range: Entry zone between R$18.00–R$18.50 (near SMA50) is more attractive; resistance at R$21.50–R$22.00 (SMA200). Suggested stop-loss below R$16.15 (below the 52-week low).
• Practical action: Hold existing positions; for new money, wait for a pullback to the R$18.00–R$18.50 area or a confirmed breakout above R$21.50 before adding.

1. Recent Price & Momentum

• Current price of R$19.45 is 29% below the 52-week high of R$27.42 and 20% above the 52-week low of R$16.21 — it sits in the lower-middle part of the range.
• The stock is above the 50-day moving average (R$18.02), but below the 200-day (R$21.57), indicating a bearish medium-term structure with a short-term rebound.
• Likely scenario: if the stock holds above R$18.00, it may attempt to move toward R$20–R$21.50; a break below R$18.00 would open a retest of the lows.

2. Valuation (P/E)

• P/E TTM of 25.23 is a premium to the broader Brazilian retail and pharmacy sector, which typically trades in the 15–20x range.
• This multiple implies the market is pricing in consistent mid-to-high single-digit earnings growth, but the current price already reflects much of that expectation.
• Unless earnings accelerate meaningfully, the stock does not offer a strong valuation-driven margin of safety at current levels.

3. Technical Analysis

• SMA50 (18.02) is below SMA200 (21.57): death-cross configuration and medium-term downtrend pressure.
• RSI(14) at 42.5: neutral, with room to move up before becoming overbought, but no strong buying conviction.
• MACD: 0.0144 vs signal -0.0015, histogram positive at 0.0159 — bullish short-term momentum is barely positive.
• Technical score: 45/100 → HOLD, consistent with a recovering but not yet confirmed uptrend.

4. Analyst Consensus

• No analyst data is available for this ticker.
• The absence of a clear analyst view means investors must rely only on technicals and valuation — which are mixed. The technical score aligns with the Hold decision, while the premium valuation reinforces the need for patience.